Everything below concerns Angiotensin IV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-28. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
== Culture and history == Antidepressant discontinuation symptoms were first reported with imipramine, the first tricyclic antidepressant (TCA), in the late 1950s, and each new class of antidepressants has brought reports of similar conditions, including monoamine oxidase inhibitors (MAOIs), SSRIs, and SNRIs. As of 2001, at least 21 different antidepressants, covering all the major classes, were known to cause discontinuation syndromes. The problem has been poorly studied, and most of the literature has been case reports or small clinical studies; incidence is hard to determine and controversial. With the explosion of use and interest in SSRIs in the late 1980s and early 1990s, focused especially on Prozac, interest grew as well in discontinuation syndromes. Some of the symptoms emerged from discussion boards where people with depression discussed their experiences with the disease and their medications; "brain zaps" or "brain shivers" was one symptom that emerged via these websites. Heightened media attention and continuing public concerns led to the formation of an expert group on the safety of SSRIs in England to evaluate all the research available prior to 2004. The group determined that the incidence of discontinuation symptoms are between 5% and 49%, depending on the particular SSRI, the length of time on the medicine and abrupt versus gradual cessation. With the lack of a definition based on consensus criteria for the syndrome, a panel met in Phoenix, Arizona, in 1997 to form a draft definition, which other groups continued to refine.
Boosted considerably by the arrival of three South African brigades during the last months of 1940, the Commonwealth forces in Kenya had expanded to three divisions by the end of the year. No. 237 Squadron was relieved by South African airmen and redeployed to the Sudan in September. Rebasing at Khartoum, No. 237 Squadron undertook regular reconnaissance, dive-bombing and strafing sorties during October and November 1940. Meanwhile, the Southern Rhodesian Anti-Tank Battery arrived in Kenya in October and, following a period of training, received 2-pounder guns and joined the front at Garissa around the turn of the new year. No. 237 Squadron was partially re-equipped during January 1941, receiving some Westland Lysander Mk IIs, but most of the squadron continued operating Hardys. The British forces in Kenya under General Alan Cunningham, including Rhodesian officers and NCOs in the King's African Rifles and the Nigeria and Gold Coast Regiments, as well as the South African 1st South African Infantry Division, advanced into Abyssinia and Italian Somaliland during late January and February 1941, starting with the occupation of the ports of Kismayo and Mogadishu. The Italians retreated to the interior. No. 237 Squadron meanwhile provided air support to the 4th Indian Infantry Division and 5th Indian Infantry Division during Lieutenant-General William Platt's offensive into Eritrea from the Sudan, attacking ground targets and engaging Italian fighters. One of the Rhodesian Hardys was shot down near Keren on 7 February with the loss of both occupants.
=== Variation === Considerable anatomic variation exists, in terms of length and point of attachment. Despite the classical description, the muscle only solely attaches to the duodenojejunal flexure in about 8% of people; it is far more common, 40 to 60% of the time to attach additionally to the third and fourth parts of the duodenum; and 20 to 30% of the time it only attaches to the third and fourth parts. Moreover, separate multiple attachments are not that uncommon. According to some authors, who use the original description by Treitz, the muscle may be divided into two sections: a ligamentous portion attaching the right crus of diaphragm to the connective tissue surrounding the coeliac artery and superior mesenteric artery; and a lower muscular portion from the connective tissue attaching to the duodenum. The superior portion is also described as the Hilfsmuskel. These two parts are now considered anatomically distinct, with the suspensory muscle referring solely to the lower structure attaching at the duodenum.
=== Nausea and vomiting === Intravenous dexamethasone is effective for the prevention of nausea and vomiting in people who had surgery and whose post-operative pain was treated with long-acting spinal or epidural spinal opioids. The combination of dexamethasone and a 5-HT3 receptor antagonist such as ondansetron is more effective than a 5-HT3 receptor antagonist alone in preventing postoperative nausea and vomiting.
Schiller (1969), lawyer, co-founder of Boies Schiller Flexner LLP Eric Eisner (1970), lawyer, former president of The Geffen Company and founder of the Young Eisner Scholars program William Barr (1971), attorney general of the United States Arthur Engoron (1971), judge presiding over the New York civil investigation of The Trump Organization Arthur Helton (1971), lawyer, refugee advocate Gerard E. Lynch (1972), judge of the United States District Court for the Southern District of New York Gary Stephen Katzmann (1973), judge on the United States Court of International Trade Robert Katzmann (1973), judge of the United States Court of Appeals for the Second Circuit Eric Holder (1973), United States attorney general under Barack Obama, deputy attorney general under Bill Clinton, United States Attorney for the District of Columbia, judge of the Superior Court of the District of Columbia Jonathan Cuneo (1974), lawyer, founding partner of Cuneo Gilbert & LaDuca, LLP Abbe Lowell (1974), partner at Chadbourne & Parke, chief minority counsel during the Impeachment of Bill Clinton Jeffrey L. Kessler (1975), co-chairman of Winston & Strawn; former global litigation chair at Dewey & LeBoeuf Douglas Letter (1975), general counsel to the United States House of Representatives since 2018 J. Richard Cohen (1976), former president of the Southern Poverty Law Center Joseph A. Greenaway Jr.
Sources: en.wikipedia.org
Special state certification in the United States is required only in four states: California, Washington, Nevada, and Louisiana. A phlebotomist can become nationally certified through many different organizations. However, California currently only accepts national certificates from six agencies. These include the American Certification Agency (ACA), American Medical Technologists (AMT), American Society for Clinical Pathology (ASCP), National Center for Competency Testing/Multi-skilled Medical Certification Institute (NCCT/MMCI), National Credentialing Agency (NCA), and National Healthcareer Association (NHA). These and other agencies such as the American Society of Phlebotomy Technicians also certify phlebotomists outside the state of California. To qualify to sit for an examination, candidates must complete a full phlebotomy course and provide documentation of clinical or laboratory experience.
A survey of patients using nonbenzodiazepine Z-drugs and benzodiazepine hypnotic users found that there was no difference in reports of adverse effects that were reported in over 41% of users and, in fact, Z-drug users were more likely to report that they had tried to quit their hypnotic drug and were more likely to want to stop taking Z-drugs than benzodiazepine users. Efficacy also did not differ between benzodiazepine and Z-drug users. A 2022 systematic review and network meta-analysis found that 40–50% of users have adverse effects from Z-drugs.
=== Disorders of consciousness === Selegiline has been studied in patients with disorders of consciousness, such as minimally conscious state, persistent vegetative state, and persistent coma, in a small open-label clinical study. It was found to be effective in enhancing arousal and promoting recovery of consciousness in some of these individuals.
This is true for example for the deprotonation of the amino acid cysteine, which exists in solution as a neutral zwitterion HS−CH2−CH(NH+3)−COO−. The two micro-constants represent deprotonation either at sulphur or at nitrogen, and the macro-constant sum here is the acid dissociation constant
Encouraging healthy habits early in life and addressing fear-avoidance behaviors in children with JIA can enhance both musculoskeletal and cardiovascular health. A Cochrane meta-analysis looking at existing RCTs showed in all studies that exercise does not have a detrimental effect on JIA. In fact, there is evidence to show that both low and high-intensity exercise programs result in improved physical function and reduced pain in children with JIA. Guidelines indicate that children with JIA should be encouraged to be physically active and can safely participate in sports without disease exacerbation. Those with actively inflamed joints should limit activities within pain limits, then gradually return to full activity following a disease flare. Studies found that a 12-week exercise program of weight-bearing exercise plus standardized muscle strengthening exercises for children with JIA led to significant improvements in bone mineral density, bringing measurements for children with JIA within the reference range of healthy children. It may be necessary to use aids like splints or casts to correct biomechanics, but prolonged splinting and casting are now rarely indicated for children with JIA. Joint injections of steroids may be helpful for children with JIA.
Sources: en.wikipedia.org
== Types == Neuromuscular fatigue can be classified as either "central" or "peripheral" depending on its cause. Central muscle fatigue manifests as an overall sense of energy deprivation, while peripheral muscle fatigue manifests as a local, muscle-specific inability to do work.
== British and Commonwealth realms == In Commonwealth realms, including the United Kingdom, Canada, Australia and New Zealand, centenarians can receive congratulatory cards from the monarch, currently King Charles III, on their 100th birthday. In the UK, greeting cards are also sent by the monarch on every birthday beginning with the 105th. In Commonwealth realms in which the monarch does not ordinarily reside, honorees can also receive congratulations from the governor-general. In Canada, application must be made through the GGS official website. Similarly, in New Zealand, honorees must apply for greetings through the official government website.
Tarlov cysts, also known as perineural cysts, are cerebrospinal fluid (CSF)-filled lesions that most commonly develop in the sacral region of the spinal canal (S1–S5), and less frequently in the cervical, thoracic, or lumbar spine. These cysts form as dilations of the nerve root sheath near the dorsal root ganglion, specifically within the perineural space between the endoneurium and perineurium. A defining feature is that the cyst walls contain nerve fibers, which often line the inner cavity of the cyst itself. This involvement of neural elements distinguishes Tarlov cysts from other extradural meningeal cysts, such as meningeal diverticula, which do not contain nerve fibers. The etiology of these cysts is not well understood; some current theories explaining this phenomenon include increased spinal fluid pressure, filling of congenital cysts with one-way valves, and/or inflammation in response to trauma and disease. They are named after an American neurosurgeon Isadore Tarlov, who described them in 1938. These cysts are often detected during MRI or CT scans. They are also observed using magnetic resonance neurography with communicating subarachnoid cysts of the spinal meninges. Cysts with diameters of 1cm or larger are more likely to be symptomatic; although cysts of any size may be symptomatic dependent on location and etiology. Some 40% of patients with symptomatic Tarlov cysts can associate a history of trauma or childbirth.
The rear corridor, forming a back-room behind the central pillar, is a barrel-vaulted rectangular room with the two corridors for side access. It was decorated by many spectacular murals, including a large mural showing the sharing of the relics, with soldiers in armour riding horses and elephants (β on the plan). The vault was lavishly decorated with flying asparas holding musical instruments. The back wall had a depiction of the Parinirvana with a reclining image of the Buddha, and asparas flying over. The murals were photographed in black and white in-situ by Charles Nouette in September 1907, but all of them were later taken to Germany by Von Le Coq. A reconstruction of the rear corridor was recently built in the Museum für Asiatische Kunst.
The cell membranes of bacteria are rich in acidic phospholipids, such as phosphatidylglycerol and cardiolipin. In contrast, the outer part of the membranes of plants and mammals is mainly composed of lipids without any net charges since most of the lipids with negatively charged headgroups are principally sequestered into the inner leaflet of the plasma membranes. Thus in the case of mammalian cells, the outer surfaces of the membranes are usually made of zwitterionic phosphatidylcholine and sphingomyelin, even though a small portion of the membrane's outer surfaces contain some negatively charged gangliosides. Therefore, the hydrophobic interaction between the hydrophobic face of amphipathic antimicrobial peptides and the zwitterionic phospholipids on the cell surface of mammalian cell membranes plays a major role in the formation of peptide-cell binding. Dual polarisation interferometry has been used in vitro to study and quantify the association to headgroup, insertion into the bilayer, pore formation and eventual disruption of the membrane.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.